A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2024 |
| Reihe/Periodikum: | Journal of Medical Economics ; volume 27, issue 1, page 445-454 ; ISSN 1369-6998 1941-837X |
| Verlag/Hrsg.: |
Informa UK Limited
|
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29185440 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1080/13696998.2024.2324612 |
